Earnings
Hi all, just a reminder of RBC analyst's expectations for CXR from his Nov.report attached here. I personally think that AMCO's contribution for Q415 is understated in his report as the rev # is basically AMCO's 2014 annual revs divided by 4, not sure if he has revised his $77 USD target since this report. What stands out to me most is the complete transformation from reliance on one market and one drug to a very diversified, very global product portfolio. GLTA. https://www.rbcinsight.com/WM/share/ResearchViewer/?YYY340_a0lQ3LRaZh+1NpNJQbmxH1Obdb3DBwBNLGtNKcq+bZcVRjN4GR75hg==&a=a